Driving Innovation: Our Team
Executive Leadership Team
Dany Valiquette
Founder, President & CEO
Dany Valiquette has almost 30 years experience as an entrepreneur in technology business development, structuring and promotion of high-value tech firms. Skilled in IP strategies and bridging science with business, he drives Glycovax’s growth through innovative approaches, strong business and technology team, and a vast professional network.
Marc Beausoleil, M.LUPD
Executive Vice-President
Marc Beausoleil brings 20+ years of expertise in leading and financing technology companies. With a master's in economic development, he has supported hundreds of ventures and served on multiple boards. He ensures Glycovax’s performance through strategic planning and team synergy.
Yacine Amrani, CPA
Chief Financial Officer
Yacine Amrani, CPA, is an experienced CFO with 20+ years in financial management of start-ups and growing companies. Skilled in financial and budget planning, cost control and reporting, he manages Glycovax’s financial structure.
Ram Vishwakarma, Ph.D.
Advisor, Drug Discovery
Ram Vishwakarma, PhD, is a renowned expert in glycobiology with 30+ years of research with 350+ publications and 50+ patents. Former VP at Piramal Healthcare and Director at CSIR-IIIM, he advanced cancer and viral therapies. Now an Advisor of Drug Discovery at Glycovax, he bridges glycobiology to vaccines.
Serge Moffett, Ph.D.
Director - Biology
Serge Moffett, PhD in biochemistry, has 24+ years of expertise molecular medicine specializing in the development of targeted medicines for cancer therapy and detection. With a broad experience in all aspects of drug development, he has contributed to the launch and growth of several biotechnology startups. He drives Glycovax’s innovative strategies against cancer and infectious diseases.
Tze Chieh Shiao, M.Sc.
Director - Glycochemistry & Analytics
Tze Chieh Shiao, MSc, is a glycochemistry expert specializing in the chemical synthesis of complex glycan molecules that contributed to 200+ scientific articles and communications. He collaborated with glycoscience pioneers to develop the first ever semi-synthetic commercialized vaccine Quimi-Hib. He drives Glycovax’s innovative glycoantigen synthesis, key to its distinctive science.
Élodie Pastural, Ph.D. RAC
Director - Regulatory Affairs & Clinical Development
Élodie Pastural, PhD in immunology, is an expert with 15+ years of experience in vaccine development. Formerly at VIDO, she led Canada's first academic COVID-19 vaccine project. Now at Glycovax, she oversees regulatory affairs and clinical development for innovative vaccines.
Daniel Boismenu, Ph.D.
Scientific Co-Founder & Special Advisor
Daniel Boismenu, PhD in chemistry, is a pioneer in proteomics and biomarker identification by mass spectrometry. With expertise in analytical protocols and pharmaceutical collaboration, he ensures top-tier quality control for Glycovax's innovative solutions.
Special Advisors
Luis Martin, Ph.D.
Scientific Advisor
Biotech leader with 30+ years’ experience in vaccine development, IP management, and team building. He led major projects like COVID-19 vaccines and collaborates with top research institutions across Canada to transform science into impactful solutions.
Pierre Dion
Advisor to the President & CEO
Formerly Senior Executive with more than 15 years experience as President and CEO of public and private companies, he is now a Strategic Advisor to CEOs and Executives.
Daniel Granger, C.M., C.Q., APR, FCPRS
Chairman of the board
Lawyer and Fellow in Public Relations and Communications, with 30 years+ experience in business development, issues management, strategic communications and government relations.
Glycovax: A Timeline of Innovation
Launching Glycovax Pharma
October 2016
Establishing Glycovax Labs at Centre Québécois d’Innovation en Biotechnologie (CQIB) Quebec, Canada
June 2017
Canadian Government Awards Funding for COVID-19 Vaccine Development
2020
Licensing Agrement with NRC for CRM197 Production
March 2021
Phase 1 Clinical Trial Application Approved
March 2023
Phase 1 Clinical Trial Enrollment Initiated
April 2023
Licensing Agreement with NRC for SLA Adjuvant
February 2024
Licensing Agreement with NRC for Pseudomonas aeruginosa Vaccine
August 2024